Home・Akciju saraksts・Arcus Biosciences Inc

Arcus Biosciences Inc

Atvērts

SektorsVeselības aprūpe

28.81 4.42

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

27.39

Max

28.58

Galvenie mērījumi
By Trading Economics
Ienākumi	-22M -128M
Pārdošana	-16M 17M
EPS	-1.02
Peļņas marža	-752.941
Darbinieki	601
EBITDA	-42M -123M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+39.86% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 5. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	229M 3.5B
Iepriekšējā atvēršanas cena	24.39
Iepriekšējā slēgšanas cena	28.81

Ziņu noskaņojums

By Acuity

79%

21%

307 / 340 Rangs Healthcare

Arcus Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. aug. 19:36 UTC

Arcus Biosciences shares are lower today, reflecting broader market dynamics and geopolitical developments impacting investor sentiment. Earlier, shares peaked before declining.

2026. g. 31. jūl. 23:16 UTC

Arcus Biosciences Inc. shares are lower in after-market hours, continuing a trend of declining prices and remaining below the 20-day moving average.

2026. g. 30. jūl. 18:03 UTC

Arcus Biosciences Inc gains today, supported by a broader market uptick despite geopolitical tensions and inflation concerns. Shares pulled back from earlier session highs.

2026. g. 29. jūl. 19:56 UTC

Macro Event

Arcus Biosciences shares are lower amid broader market pressures from steady interest rates and rising crude oil prices, marking five consecutive sessions of decline.

2026. g. 28. jūl. 20:06 UTC

Arcus Biosciences Inc shares are lower today, reflecting broader market trends and declines in Asian markets, including significant losses in the Nikkei 225 Index.

2026. g. 27. jūl. 21:01 UTC

Arcus Biosciences Inc shares declined in after-market hours, continuing a downward trend over the last four sessions. No specific news was identified to explain the move.

2026. g. 24. jūl. 19:06 UTC

News

Arcus Biosciences has signed a clinical supply agreement with AVEO to evaluate casdatifan with tivozanib. Shares are trading lower, reflecting unusual weakness.

2026. g. 22. jūl. 20:13 UTC

Arcus Biosciences shares are higher in after-market hours. Broader market volatility is influenced by rising crude oil prices and geopolitical tensions.

2026. g. 21. jūl. 19:36 UTC

Arcus Biosciences shares are higher today, supported by overall market strength and positive sentiment in the biotechnology sector. The stock has advanced notably since Monday.

2026. g. 20. jūl. 18:06 UTC

News

H.C. Wainwright raised Arcus Biosciences' price target to $45 from $32, maintaining a Buy rating. Shares are higher today following the analyst's upgrade.

Salīdzinājums

Cenas izmaiņa

Arcus Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

39.86% augšup

Prognoze 12 mēnešiem

Vidējais 38.63 USD 39.86%

Augstākais 47 USD

Zemākais 22 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Arcus Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

9 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 9 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Arcus Biosciences Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

307 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.